Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca to pay $1.1bn tax settlement

AstraZeneca has reached an agreement with UK and US authorities to pay $1.1bn to resolve all US transfer pricing and related valuation matters covering 2000 to 2010

AstraZeneca (AZ) has reached an agreement with UK and US authorities to pay $1.1bn to resolve all US transfer pricing and related valuation matters covering 2000 to 2010. The costs relate to an Advance Pricing Agreement relating to transfer pricing arrangements for AstraZeneca's US business for the period from 2002 to the end of 2014. AstraZeneca will make the agreed payment during 2011.

AZ had previously set aside $2.3bn to resolve this issue. As a result, it is now able to release $0.5bn, increasing the company's earnings per share for Q1 2011.

AZ has also reached agreement with the US tax authorities relating to matters arising as a result of integration of AZ's US businesses in 2000 following the global AstraZeneca merger in 1999.

As a result of the agreement, AZ's effective tax rate for 2011 has decreased by around 6 per cent resulting in an increase of earnings per share to around $6.90 to $7.20 from $6.45 to $6.75.

29th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics